KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Current Assets (2019 - 2025)

Historic Current Assets for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $1.5 billion.

  • Royalty Pharma's Current Assets fell 1520.68% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year decrease of 1520.68%. This contributed to the annual value of $1.5 billion for FY2025, which is 1520.68% down from last year.
  • As of Q4 2025, Royalty Pharma's Current Assets stood at $1.5 billion, which was down 1520.68% from $1.8 billion recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's Current Assets peaked at $3.5 billion during Q2 2022, and registered a low of $1.3 billion during Q4 2023.
  • In the last 5 years, Royalty Pharma's Current Assets had a median value of $2.4 billion in 2021 and averaged $2.3 billion.
  • In the last 5 years, Royalty Pharma's Current Assets crashed by 5012.76% in 2023 and then soared by 4143.38% in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's Current Assets stood at $2.9 billion in 2021, then dropped by 11.23% to $2.6 billion in 2022, then plummeted by 50.13% to $1.3 billion in 2023, then soared by 41.43% to $1.8 billion in 2024, then dropped by 15.21% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q4 2025, $1.8 billion for Q3 2025, and $1.5 billion during Q2 2025.